ROCN, CMC/CSC, C-OBE, BCPMP & NRCME: practice drill
10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.
Timed mock exam
15 questions in 18 minutes, drawn from every topic. No answers shown until the end, then a full score breakdown, your weakest topics and a review of what you missed.
Prices are in US dollars, plus tax where it applies. Stripe, our payment processor, calculates tax at checkout.
All sales are final. If something is really wrong, such as a duplicate charge or a purchase that does not unlock what you bought, write to support@careerexampro.com and we will put it right.
One-time payment. Nothing renews.
You have an exam ticket for this practice test. Start the timed mock exam to use it.
Exam Snapshot & Official Blueprint
Official Exam Fee
$200 (NCLEX-RN) · $129 (PTCB PTCE)
Format & Time Limit
NCLEX 2026 Test Plan (Apr 2026) · PTCE 2026 Blueprint (Jan 2026)
Passing Standard
NCLEX CAT logit standard · PTCE 1400/1600
Typical Prep Incumbents
$150–$400+ (UWorld / Kaplan)
Official Domain Breakdown
Exam Domain
Weight
NCSBN 2026 Clinical Judgment Measurement Model (CJMM) & Delegation
50%
PTCB Jan 2026 Expanded Federal Requirements (18.75% — DSCSA, REMS, DEA)
Delegation Golden Rule: Never delegate EAT (Evaluate, Assess initial/unstable, Teach) to UAP/LPN; assign stable, predictable patients with standard protocols to LPNs.
PTCB Jan 2026 Federal Update: Federal Requirements jumped from 12.5% to 18.75%—master DSCSA interoperable electronic EPCIS tracing, suspect product quarantine + FDA Form 3911 (24 hrs), REMS ETASU, and CMEA pseudoephedrine limits (3.6 g/day, 9 g/30 days).
Frequently Asked Questions
What changed on the PTCB PTCE in January 2026?
PTCB raised Federal Requirements from 12.5% to 18.75% to emphasize DSCSA serialization/tracing, DEA controlled substance rules, and REMS safety programs.
Exact question counts, passing scores, and allowed reference materials vary by testing window and state/agency. Always confirm current rules with the official testing provider.
Sample questions
A 65-year-old patient taking scheduled oral oxycodone for chronic cancer pain reports hard, infrequent stools (one bowel movement every 5 days with straining, Bowel Function Index score 68) despite daily scheduled polyethylene glycol and senna. Physical examination and abdominal imaging exclude mechanical gastrointestinal obstruction. What is the most evidence-based next pharmacologic step?
Discontinue senna and polyethylene glycol and switch to docusate sodium 100 mg twice daily plus psyllium husk fiber monotherapy.
Reassure the patient and wait 4 additional weeks without changing therapy because complete physiologic tolerance to opioid-induced constipation develops rapidly.
Administer oral naltrexone 50 mg daily to block enteric mu-opioid receptors while preserving full central nervous system opioid analgesia.
Initiate a peripherally acting mu-opioid receptor antagonist (PAMORA) such as naloxegol, naldemedine, or subcutaneous methylnaltrexone.
Show the answer
D. Initiate a peripherally acting mu-opioid receptor antagonist (PAMORA) such as naloxegol, naldemedine, or subcutaneous methylnaltrexone.
Patients do not develop tolerance to opioid-induced constipation (OIC). Per AGA and NCCN guidelines, docusate alone is ineffective for OIC and bulk-forming fiber (psyllium) can worsen impaction. When OIC persists despite scheduled osmotic and stimulant laxatives—and mechanical GI obstruction has been ruled out—the recommended step is a PAMORA (naloxegol, naldemedine, or methylnaltrexone), which selectively blocks peripheral enteric mu-opioid receptors without crossing the blood-brain barrier to reverse CNS analgesia (unlike systemic naltrexone, which precipitates acute withdrawal and loss of analgesia).
Reference: AGA Clinical Practice Guideline on the Medical Management of Opioid-Induced Constipation / BPS BCPMP Blueprint
During week 5 of whole-breast external beam radiation therapy (EBRT), a patient develops patchy moist desquamation with serous exudate and tenderness in the inframammary fold (CTCAE Grade 2). Which nursing intervention aligns with evidence-based radiation dermatitis management?
Apply a thick layer of zinc oxide barrier paste over the inframammary fold 30 minutes before each daily fraction to protect exposed dermis from scatter.
Cleanse gently with lukewarm water, apply a non-adherent hydrogel or silicone foam dressing, and avoid heavy ointments right before beam delivery.
Scrub the weeping area twice daily with chlorhexidine solution, leave it open to dry heat from a warm hair dryer, and secure gauze with paper tape.
Apply over-the-counter 1% silver sulfadiazine cream immediately prior to each radiation session and instruct the patient to stop washing the treated breast.
Show the answer
B. Cleanse gently with lukewarm water, apply a non-adherent hydrogel or silicone foam dressing, and avoid heavy ointments right before beam delivery.
Moist desquamation requires moist wound healing with gentle cleansing (lukewarm water and mild pH-neutral cleanser if needed), patting dry, and atraumatic non-adherent dressings such as hydrogel sheets or soft silicone foam without adhesive tape in the field. Thick metallic or petroleum-based ointments (such as zinc oxide or silver sulfadiazine) applied right before treatment can act as a tissue-equivalent bolus, increasing surface radiation dose and worsening skin injury; harsh antiseptics, scrubbing, and heat further damage regenerating keratinocytes.
Reference: ONS Guidelines for Cancer Treatment-Related Skin Toxicities / MASCC Radiodermatitis Clinical Practice Guidelines
A 54-year-old patient with chronic lumbar radiculopathy has been stable for 4 years on oral oxycodone 15 mg every 6 hours (90 MME/day) and clonazepam 0.5 mg twice daily prescribed by psychiatry for panic disorder. Applying the CDC Clinical Practice Guideline for Prescribing Opioids (2022–2026), which clinical action best reflects current evidence-based standards?
Abruptly discontinue oxycodone today to comply with a mandatory federal 50 MME/day ceiling, because rapid cessation carries minimal risk of withdrawal or self-harm.
Offer naloxone with overdose education, optimize multimodal nonopioid analgesia, and coordinate gradual risk reduction rather than abrupt cessation.
Convert the patient directly to an extended-release opioid at 120 MME/day to eliminate breakthrough peaks and discontinue naloxone because he is opioid-tolerant.
Refuse to offer naloxone unless the patient has a prior emergency department visit for illicit heroin overdose, as prescription opioids rarely cause respiratory depression.
Show the answer
B. Offer naloxone with overdose education, optimize multimodal nonopioid analgesia, and coordinate gradual risk reduction rather than abrupt cessation.
The CDC Clinical Practice Guideline for Prescribing Opioids (2022, current through 2026) explicitly advises against abrupt opioid discontinuation or inflexible forced tapering in physically dependent patients due to severe risks of acute withdrawal, unmanaged pain, suicidal ideation, and transition to illicit opioids. Instead, clinicians should optimize multimodal nonopioid therapies, coordinate with behavioral health on benzodiazepine-opioid co-prescribing risks, and proactively offer naloxone whenever overdose risk factors exist—including dosages >=50 MME/day or concurrent benzodiazepine use.
Reference: CDC Clinical Practice Guideline for Prescribing Opioids for Pain (MMWR 2022; active 2026 standard) / BPS BCPMP
Taking this exam soon?
Tell us which exam domains or calculation drills you want more practice on.